Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01043640
Other study ID # 2009LS088
Secondary ID MT2009-19
Status Completed
Phase Phase 2
First received January 5, 2010
Last updated January 9, 2018
Start date December 2009
Est. completion date June 2017

Study information

Verified date September 2017
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. This may be an effective treatment for inherited metabolic disorders.

Purpose: The design of this study is to achieve donor cell engraftment in patients with standard-risk inherited metabolic diseases with limited peri-transplant morbidity and mortality. This will be achieved through the administration of the chemotherapy regimen described. The intention is to follow transplanted patient for years after transplant monitoring them for complications of their disease and assisting families with a multifaceted interdisciplinary approach.


Description:

Primary Objective:

- To estimate the proportion of patients with donor derived engraftment at day 100 post transplant as defined by 80% or greater donor cells in the CD3 (T cell) fraction

Secondary Objectives:

- To determine the incidence and severity of graft-versus-host disease (GVHD) by day 100

- To determine the incidence of peri-transplant mortality (death by day 100)

- To monitor donor cell chimerism at various time points following allogeneic transplantation with this transplant regimen as determined at day 28, 42, 100, 6 months and yearly for 5 years.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date June 2017
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender All
Age group N/A to 21 Years
Eligibility Inclusion Criteria:

- Must have diagnosis of one of the following: mucopolysaccharidosis disorder, glycoprotein metabolic disorder, sphingolipidoses or inherited leukodystrophy, peroxisomal disorder or other inherited diseases of metabolism

- Must have an acceptable graft source as defined by University of Minnesota criteria

- Adequate organ function

Exclusion Criteria:

- Pregnant - menstruating females must have a negative serum pregnancy test within 14 days of treatment start

- Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology

Study Design


Related Conditions & MeSH terms

  • Adrenoleukodystrophy
  • Adrenoleukodystrophy (ALD)
  • Alpha Mannosidosis
  • alpha-Mannosidosis
  • Aspartylglucosaminuria
  • Disease
  • Fucosidosis
  • Hunter Syndrome
  • Hurler Syndrome
  • Krabbe Disease
  • Leukodystrophy, Globoid Cell
  • Leukodystrophy, Metachromatic
  • Maroteaux-Lamy Syndrome
  • Metabolic Diseases
  • Metachromatic Leukodystrophy (MLD)
  • Mucopolysaccharidoses
  • Mucopolysaccharidosis
  • Mucopolysaccharidosis I
  • Mucopolysaccharidosis II
  • Mucopolysaccharidosis VI
  • Mucopolysaccharidosis VII
  • Peroxisomal Disorders
  • Sly Syndrome
  • Sphingolipidoses
  • Syndrome

Intervention

Drug:
Campath-1H
Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
Cyclophosphamide
Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
Busulfan
Administered every 6 hours: If < or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If > 12 kg then 0.8 mg/kg/dose IV
Procedure:
Allogeneic stem cell transplantation
Administered > 24 hours after last dose of busulfan.
Drug:
Cyclosporine A
2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight: If body weight is = 40 kg dosing will be 3 times daily If body weight is > 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).
Mycophenolate Mofetil
15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC>500 x 10^6 neutrophils/L x 3 days and chimerism >90%), whichever is later.

Locations

Country Name City State
United States Masonic Cancer Center, University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients With Donor Derived Engraftment Donor derived engraftment is defined as 80 percent or greater donor cells in the recipient's bone marrow and blood cells. Day 100 Post Transplant
Secondary Number of Patients With Grade 0 Graft-Versus-Host Disease (GVHD) GVHD grading is performed using modified Glucksberg criteria and is as follows:
grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Day 100 Post Transplant
Secondary Number of Patients With Grade 1 Graft-Versus-Host Disease (GVHD) GVHD grading is performed using modified Glucksberg criteria and is as follows:
grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Day 100 Post Transplant
Secondary Number of Patients With Grade 2 Graft-Versus-Host Disease (GVHD) GVHD grading is performed using modified Glucksberg criteria and is as follows:
grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Day 100 Post Transplant
Secondary Number of Patients With Grade 3 Graft-Versus-Host Disease (GVHD) GVHD grading is performed using modified Glucksberg criteria and is as follows:
grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Day 100 Post Transplant
Secondary Number of Patients With Grade 4 Graft-Versus-Host Disease (GVHD) GVHD grading is performed using modified Glucksberg criteria and is as follows:
grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Day 100 Post Transplant
Secondary Number of Patients Who Died Peri-Transplant Peri-transplant is defined as within 100 days of transplant. By Day 100 Post Transplant
Secondary Donor Cell Chimerism Following Transplant Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. Day 28
Secondary Donor Cell Chimerism Following Transplant Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. Day 42
Secondary Donor Cell Chimerism Following Transplant Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. Day 100
Secondary Donor Cell Chimerism Following Transplant Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. 6 months
Secondary Donor Cell Chimerism Following Transplant Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. One year
See also
  Status Clinical Trial Phase
Recruiting NCT05422482 - A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients With MPS Ⅱ Phase 1
Completed NCT00630747 - Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Phase 2/Phase 3
Completed NCT03292887 - Hunter Outcome Survey (HOS)
Active, not recruiting NCT02455622 - Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Phase 4
Completed NCT00882921 - An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
Completed NCT00920647 - A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Phase 1/Phase 2
Completed NCT01449240 - Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Completed NCT03920540 - A Study of GC1111 in Hunter Syndrom Patients Phase 3
Recruiting NCT06031259 - Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment Phase 2/Phase 3
Completed NCT02055118 - Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment Phase 2/Phase 3
Completed NCT01645189 - Safety and Efficacy of Hunterase Phase 3
Completed NCT00937794 - Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
Recruiting NCT02171104 - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Phase 2
Recruiting NCT02044692 - The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients N/A
Completed NCT03582449 - Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)
Completed NCT01822184 - Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
Recruiting NCT05494593 - A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) Phase 4
Completed NCT00607386 - Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Phase 4
Terminated NCT01330277 - Biomarkers for Hunter Syndrome
Completed NCT01506141 - An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment Phase 1/Phase 2